Canopy Growth (NASDAQ:CGC) CEO Sells $131,174.07 in Stock

Posted by Brian Himes on Jun 22nd, 2026

Canopy Growth Corporation (NASDAQ:CGC – Get Free Report) CEO Luc Mongeau sold 135,231 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $0.97, for a total transaction of $131,174.07. Following the transaction, the chief executive officer directly owned 1,723,913 shares in the company, valued at approximately $1,672,195.61. This trade represents a 7.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Canopy Growth Trading Down 1.0%

Shares of NASDAQ CGC traded down $0.01 during trading hours on Monday, reaching $0.96. The stock had a trading volume of 3,924,601 shares, compared to its average volume of 10,644,430. The company has a current ratio of 3.34, a quick ratio of 2.64 and a debt-to-equity ratio of 0.31. The firm has a market cap of $386.78 million, a price-to-earnings ratio of -1.62 and a beta of 0.77. The business’s fifty day moving average price is $1.08 and its two-hundred day moving average price is $1.13. Canopy Growth Corporation has a 52-week low of $0.84 and a 52-week high of $2.38.

Canopy Growth (NASDAQ:CGC – Get Free Report) last announced its quarterly earnings data on Monday, June 15th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.11). The firm had revenue of $51.22 million during the quarter, compared to the consensus estimate of $53.43 million. Canopy Growth had a negative return on equity of 26.95% and a negative net margin of 75.27%. Analysts expect that Canopy Growth Corporation will post -0.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on CGC shares. Canaccord Genuity Group assumed coverage on Canopy Growth in a research note on Friday, March 27th. They set a “buy” rating on the stock. Wall Street Zen cut shares of Canopy Growth from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Weiss Ratings downgraded shares of Canopy Growth from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 15th. Finally, ATB Cormark Capital Markets upgraded shares of Canopy Growth from a “strong sell” rating to a “moderate buy” rating in a report on Tuesday, March 17th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold”.

Get Our Latest Report on CGC

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd lifted its stake in shares of Canopy Growth by 723.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,595,330 shares of the company’s stock worth $5,239,000 after purchasing an additional 4,037,281 shares during the last quarter. Millennium Management LLC grew its stake in Canopy Growth by 196.9% in the third quarter. Millennium Management LLC now owns 3,137,696 shares of the company’s stock valued at $4,579,000 after purchasing an additional 2,080,994 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Canopy Growth by 19,571.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,022,197 shares of the company’s stock worth $2,305,000 after purchasing an additional 2,011,917 shares in the last quarter. Lazard Asset Management LLC bought a new position in Canopy Growth in the first quarter worth about $1,716,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Canopy Growth during the third quarter valued at about $1,767,000. 3.33% of the stock is owned by institutional investors.

About Canopy Growth

(Get Free Report)

Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.

The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.